Skip to main content

JAK/TYK2

Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies

Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.

Vaccination with Shingrix: Does it work for patients on JAKi?

Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.

RT @Janetbirdope: What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumato

Janet Pope Janetbirdope

10 months 1 week ago
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
RT @DrMiniDey: Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadaciti

Mrinalini Dey DrMiniDey

10 months 1 week ago
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5
RT @KDAO2011: Which JAKi will you use after MTX failure? #acr20 @rheumnow

k dao KDAO2011

10 months 1 week ago
Which JAKi will you use after MTX failure? #acr20 @rheumnow
RT @RADoctor: Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 2

Jeffrey Curtis RADoctor

10 months 1 week ago
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,

Robert B Chao, MD doctorRBC

10 months 1 week ago

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

RT @DrMiniDey: Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis pati

Mrinalini Dey DrMiniDey

10 months 1 week ago
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD
RT @RichardPAConway: Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients tre

Richard Conway RichardPAConway

10 months 1 week ago
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial o

Dr. John Cush RheumNow

10 months 1 week ago
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
×